...
首页> 外文期刊>Journal of Surgical Oncology >Comparison of long‐term clinical outcomes among different vascularized lymph node transfers: 6‐year experience of a single center's approach to the treatment of lymphedema
【24h】

Comparison of long‐term clinical outcomes among different vascularized lymph node transfers: 6‐year experience of a single center's approach to the treatment of lymphedema

机译:不同血管化淋巴结转移中长期临床结果的比较:单一中心治疗淋巴米肿瘤的6年体验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background This study evaluated the long‐term clinical outcomes among different vascularized lymph node transfers (VLNT) used at our institution. Methods Between July 2010 and July 2016, all patients with International Society of Lymphology (ISL) stages II‐III who underwent VLNT were evaluated. Demographic and clinical data (limb circumference, infectious episodes, lymphoscintigraphic studies) were recorded pre‐operatively. Clinical outcomes, complications, and additional excisional procedures were analyzed post‐operatively. At least 2‐year follow‐up was required for inclusion. Results Overall, 83 patients (Stage II:47, Stage III:36) met the inclusion criterion. Mean follow‐up was 32.8 months (range, 24‐49). Lymph node flaps used were groin ( n ?=?13), supraclavicular ( n ?=?25), gastroepiploic ( n ?=?42), ileocecal ( n ?=?2), and appendicular ( n ?=?1). Total mean circumference reduction rate was 29.1% (Stage II) and 17.9% (Stage III) ( P ??0.05). A paired t ‐test showed that VLNT significantly decreased the number of infections ( P? ?0.05). Three patients reported no improvement of the symptoms. Major complications included one flap loss and one donor site hematoma. After the period of follow‐up, 18 patients (21.7%) underwent additional excisional procedures. Conclusion VLNT is a promising technique used for the treatment of lymphedema and appears to be more effective in moderate stages (Stage II). Patients with advanced stage lymphedema (Stage III) may benefit from additional excisional procedures.
机译:背景技术本研究评估了我们机构使用的不同血管化淋巴结转移(VLNT)中的长期临床结果。方法2010年7月至2016年7月,评估了所有淋巴管学(ISL)阶段II-III患者的患者。预先记录人口统计学和临床​​数据(肢体周长,传染病,淋巴动物研究)。可操作地分析临床结果,并发症和额外的切除程序。包含至少2年的随访所需的。结果总体而言,83名患者(第三阶段:47,第三阶段:36)达到了纳入标准。平均随访32.8个月(范围,24-49)。使用的淋巴结瓣腹股沟(n?=α13),supraclavicular(n?=Δ25),胃窦(n?=Δ22),对齐(n?=Δ2),附加(n?=?1) 。总平均周长减少率为29.1%(阶段II)和17.9%(III阶段)(P 1 0.05)。成对的T -Test显示VLNT显着降低了感染的数量(p≤≤0.05)。三名患者报告没有改善症状。主要并发症包括一个皮瓣损失和一个供体部位血肿。后续期后,18名患者(21.7%)接受了额外的切除程序。结论VLNT是一种用于治疗淋巴水肿的有希望的技术,似乎在中等阶段更有效(II阶段)。患有晚期淋巴水肿(第三阶段)的患者可能会受益于额外的切除程序。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号